Study shows IV Ketamine "Significantly Reduces" Bipolar Depression Symptoms

Sponsored by

Want chef-crafted, dietitian-designed meals ready in 2 minutes?

Try Factor, America's #1 ready-to-eat meal delivery service.

Made from ingredients you recognize. Whole food. Nothing unnecessary. Let’s eat real.

Get 50% off your first Factor box + Free Breakfast for a year *1 free breakfast item per box for 1 year while subscription active.

Try Factor Now

Study shows IV Ketamine "Significantly Reduces" Bipolar Depression Symptoms

Treatment deemed effective, “without triggering mania or psychosis” in patients with Bipolar Disorder

By Jack Gorsline

Source: Psychedelic State(s) of America

A recent randomized clinical trial published in JAMA Psychiatryhasfound that repeated intravenous (IV) ketamine infusions can effectively relieve symptoms of treatment-resistant bipolar depression. Crucially, the intervention achieved these results without triggering mania or psychosis, clearing a major historical hurdle in treating the disorder. Dubbed the Ket-BD trial, the study evaluated 68 adult outpatients with a primary diagnosis of either bipolar I or bipolar II disorder. At the time of the trial, these individuals were currently experiencing a moderate-to-severe major depressive episode. Because these patients had already tried and failed at least two standard evidence-based pharmacotherapy trials, they represent a highly treatment-resistant population that is uniquely challenging for modern psychiatry to treat.

Taking place at three separate clinical sites in Ontario, Canada, the trial administered four 40-minute IV infusions to participants over a two-week period. Patients were randomly assigned to one of two groups: one receiving flexible doses of ketamine, and the other receiving an active placebo. Importantly, the study was designed as an adjunctive therapy. Instead of replacing existing medication regimens, the infusions were safely provided alongside the patients' existing, stable doses of standard mood stabilizers or antipsychotic medications.

By the end of the 14-day study window, patients receiving IV ketamine experienced a clinically meaningful drop in depression severity compared to the active placebo group. The researchers measured these outcomes using the standard Montgomery-Åsberg Depression Rating Scale (MADRS). Those receiving ketamine scored an average of 7.3 points lower on the MADRS than their peers in the control group, a margin that easily surpasses the benchmark for clinical significance.

When looking beyond average scores to individual patient outcomes, the difference in overall success rates was striking. Over one-third (35.3%) of the participants in the ketamine group met the strict criteria for clinical response, indicating that their depressive symptoms had been slashed by more than half. In stark contrast, only 11.8% of the control group met this same response threshold. Furthermore, the study measured full remission—the complete alleviation of depressive symptoms. Exactly 17.6% of the ketamine cohort achieved full remission of their depression, exactly double the 8.8% remission rate observed in the placebo arm.

Historically, patients with bipolar disorder are frequently left out of psychedelic and ketamine clinical research. This exclusion stems from widespread fears within the psychiatric community that fast-acting antidepressants could provoke sudden manic episodes, rapid mood cycling, or psychosis. Notably, this trial directly challenged those safety concerns, observing zero cases of mania, hypomania, psychosis, or suicide attempts in either the ketamine or the control group. Only one person in each arm reported brief, sub-threshold hypomanic symptoms.

"Ketamine was not associated with treatment-emergent mania or psychosis, a safety concern that has often led to the exclusion of BD from previous trials and clinical practice," the study authors stated.

Designing rigorous clinical trials for dissociative and psychoactive drugs is notoriously tricky, as patients typically realize when they have been administered a mind-altering substance, leading to functional unblinding. To preserve the integrity and blind status of the Ket-BD trial, researchers utilized midazolam, a psychoactive sedative, as the active control. This active placebo successfully masked the treatment assignment for most patients. The tactic paid off effectively early in the process: following the very first infusion, less than half (47%) of the study participants were able to correctly guess their treatment allocation.

The profound relief from depressive symptoms proved to have sustained short-term benefits, remaining significantly greater than the placebo for one week following the final dose. However, symptoms gradually began creeping back after the infusions were stopped. The research team noted that this trajectory aligns with standard expectations for discontinuing an efficacious psychiatric intervention. Consequently, this highlights that ongoing maintenance ketamine infusions would likely be necessary to preserve longer-term antidepressant efficacy and keep patients feeling well.

While earlier studies on bipolar disorder primarily looked at single-dose, proof-of-concept treatments, the study authors highlighted the novelty of their multi-dose approach: "To our knowledge, the present study is the first RCT to evaluate the antidepressant efficacy, safety, and tolerability of serial ketamine infusions for TRBD".

These new findings do not exist in a vacuum; rather, they strongly reinforce over ten years of established psychiatric research demonstrating intravenous ketamine’s potential to safely alleviate mood disorders. The foundation of this specific clinical trajectory traces back over a decade to a pivotal randomized controlled trial published in Biological Psychiatry in 2012 that concluded a single intravenous infusion of ketamine showed potential to produce rapid antidepressant and anti-suicidal effects in patients with bipolar depression in just 40 minutes. The Zarate study documented an overwhelming clinical response, with 79% of patients responding positively to the ketamine treatment compared to absolutely zero response (0%) in the placebo group.

Subsequent analyses have continued to build on that early promise. A 2021 systematic review published in the Journal of Clinical Psychopharmacology, synthesized data from multiple trials to further validate these outcomes. By analyzing five separate studies involving a total of 110 subjects, the review confirmed that intravenous racemic ketamine effectively improves depressive symptoms, suicidal ideation, and anhedonia. Crucially, the 2021 review also concluded that ketamine interventions did not increase the risk of mania symptoms, perfectly mirroring the positive safety and tolerability profile observed in the newly published 14-day serial infusion trial.

With these highly encouraging efficacy and safety metrics now established for serial infusions, the researchers are pushing for larger, phase 3 clinical trials. These future studies will be essential to test longer treatment periods and establish definitive protocols for maintenance therapy. Above all, the research team stressed the desperate need for fresh therapeutic alternatives for a patient population that has long been underserved by conventional medicine.

"Currently available treatments are often ineffective for TRBD, with new treatments urgently needed," the authors concluded.